{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:47:24Z","timestamp":1789015644382,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report a 19-year-old Vietnamese woman who experienced several life-threatening bleeding events, including ovarian hemorrhage. Blood analysis revealed a decreased fibrinogen level with markedly elevated fibrinogen\/fibrin degradation products and D-dimer levels. Despite hemostatic surgery and administration of several medications, such as nafamostat mesylate, tranexamic acid, and unfractionated heparin, the coagulation abnormalities were not corrected, and the patient experienced repeated hemorrhagic events. We found that administration of recombinant human thrombomodulin (rhTM) remarkably improved the patient\u2019s pathophysiology. Screening and sequencing of the TM gene (THBD) revealed a previously unreported homozygous variation: c.793T&amp;gt;A (p.Cys265Ser). Notably, the Cys265 residue forms 1 of 3 disulfide bonds in the epidermal growth factor (EGF)\u2013like domain 1 of TM. Transient expression experiments using COS-1 cells demonstrated markedly reduced expression of TM-Cys265Ser on the plasma membrane relative to wild-type TM. The TM-Cys265Ser mutant was intracellularly degraded, probably because of EGF-like domain 1 misfolding. The reduced expression of TM on the endothelial cell membrane may be responsible for the disseminated intravascular-coagulation\u2013like symptoms observed in the patient. In summary, we identified a novel TM variant, c.793T&amp;gt;A (p.Cys265Ser). Patients homozygous for this variant may present with severe bleeding events; rhTM should be considered a possible treatment option for these patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003814","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T22:57:57Z","timestamp":1630623477000},"page":"3830-3838","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["A novel homozygous variant of the thrombomodulin gene causes a hereditary bleeding disorder"],"prefix":"10.1182","volume":"5","author":[{"given":"Makoto","family":"Osada","sequence":"first","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Osaka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kokame","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Osaka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Denda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisako","family":"Kunieda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7148-9278","authenticated-orcid":false,"given":"Maki","family":"Hirao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-5947","authenticated-orcid":false,"given":"Seiji","family":"Madoiwa","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Okumura","sequence":"additional","affiliation":[{"name":"Department of Biomedical Laboratory Sciences, School of Medicine and Health Sciences, Shinshu University, Matsumoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Keio University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuiko","family":"Tsukada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2180-4238","authenticated-orcid":false,"given":"Takahide","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"issue":"2","key":"2021100515301499400_B1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2017-12-768994","article-title":"Exploring traditional and nontraditional roles for thrombomodulin","volume":"132","author":"Loghmani","year":"2018","journal-title":"Blood."},{"issue":"20","key":"2021100515301499400_B2","doi-asserted-by":"crossref","first-page":"12135","DOI":"10.1074\/jbc.273.20.12135","article-title":"Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C","volume":"273","author":"Kokame","year":"1998","journal-title":"J Biol Chem."},{"key":"2021100515301499400_B3","first-page":"614545","article-title":"Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis","volume":"2012","author":"Okamoto","year":"2012","journal-title":"Crit Care Res Pract."},{"issue":"2","key":"2021100515301499400_B4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood.V75.2.329.329","article-title":"Structure and function of thrombomodulin: a natural anticoagulant","volume":"75","author":"Dittman","year":"1990","journal-title":"Blood."},{"issue":"2","key":"2021100515301499400_B5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/14728222.2016.1086750","article-title":"Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases","volume":"20","author":"Ito","year":"2016","journal-title":"Expert Opin Ther Targets."},{"issue":"4","key":"2021100515301499400_B6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12185-012-1059-0","article-title":"Protein C anticoagulant and cytoprotective pathways","volume":"95","author":"Griffin","year":"2012","journal-title":"Int J Hematol."},{"issue":"14","key":"2021100515301499400_B7","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1016\/S0021-9258(18)34276-5","article-title":"Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation","volume":"257","author":"Esmon","year":"1982","journal-title":"J Biol Chem."},{"issue":"28","key":"2021100515301499400_B8","doi-asserted-by":"crossref","first-page":"16603","DOI":"10.1074\/jbc.271.28.16603","article-title":"TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex","volume":"271","author":"Bajzar","year":"1996","journal-title":"J Biol Chem."},{"issue":"7","key":"2021100515301499400_B9","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1538-7836.2003.00306.x","article-title":"Thrombomodulin","volume":"1","author":"Weiler","year":"2003","journal-title":"J Thromb Haemost."},{"issue":"6","key":"2021100515301499400_B10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1242\/dev.128.6.827","article-title":"Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block","volume":"128","author":"Isermann","year":"2001","journal-title":"Development."},{"issue":"3","key":"2021100515301499400_B11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1073\/pnas.92.3.850","article-title":"Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system","volume":"92","author":"Healy","year":"1995","journal-title":"Proc Natl Acad Sci USA."},{"issue":"9","key":"2021100515301499400_B12","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1161\/hq0901.094496","article-title":"Characterization of a mouse model for thrombomodulin deficiency","volume":"21","author":"Weiler","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"2021100515301499400_B13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/01.CIR.96.1.15","article-title":"Thrombomodulin gene mutations associated with myocardial infarction","volume":"96","author":"Ireland","year":"1997","journal-title":"Circulation."},{"issue":"4","key":"2021100515301499400_B14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med."},{"issue":"1","key":"2021100515301499400_B15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000490201","article-title":"Thrombomodulin and endothelial dysfunction: A disease-modifier shared between malignant hypertension and atypical hemolytic uremic syndrome","volume":"140","author":"Demeulenaere","year":"2018","journal-title":"Nephron."},{"issue":"4","key":"2021100515301499400_B16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1527-3466.2000.tb00055.x","article-title":"ART-123:Recombinant human soluble thrombomodulin","volume":"18","author":"Mohri","year":"2006","journal-title":"Cardiovasc Drug Rev."},{"issue":"20","key":"2021100515301499400_B17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2019.5358","article-title":"Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis associated coagulopathy: The SCARLET randomized clinical trial","volume":"321","author":"Vincent","year":"2019","journal-title":"JAMA."},{"issue":"10","key":"2021100515301499400_B18","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/ATVBAHA.107.150631","article-title":"Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes","volume":"28","author":"Ito","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"7809","key":"2021100515301499400_B19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature."},{"issue":"1","key":"2021100515301499400_B20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13054-019-2552-0","article-title":"Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential","volume":"23","author":"Ito","year":"2019","journal-title":"Crit Care."},{"issue":"6777","key":"2021100515301499400_B21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/35006683","article-title":"Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex","volume":"404","author":"Fuentes-Prior","year":"2000","journal-title":"Nature."},{"issue":"3","key":"2021100515301499400_B22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/73302","article-title":"Solution structure of the smallest cofactor-active fragment of thrombomodulin","volume":"7","author":"Wood","year":"2000","journal-title":"Nat Struct Biol."},{"issue":"30","key":"2021100515301499400_B23","doi-asserted-by":"crossref","first-page":"22942","DOI":"10.1074\/jbc.M001760200","article-title":"Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation","volume":"275","author":"Wang","year":"2000","journal-title":"J Biol Chem."},{"issue":"9","key":"2021100515301499400_B24","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1172\/JCI2006","article-title":"A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state","volume":"101","author":"Weiler-Guettler","year":"1998","journal-title":"J Clin Invest."},{"issue":"4","key":"2021100515301499400_B25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1172\/JCI200113077","article-title":"Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis","volume":"108","author":"Isermann","year":"2001","journal-title":"J Clin Invest."},{"issue":"15","key":"2021100515301499400_B26","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/bloodadvances.2017005058","article-title":"Variable phenotypic penetrance of thrombosis in adult mice after tissue-selective and temporally controlled Thbd gene inactivation","volume":"1","author":"van Mens","year":"2017","journal-title":"Blood Adv."},{"issue":"3","key":"2021100515301499400_B27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm825","article-title":"The thrombomodulin-protein C system is essential for the maintenance of pregnancy","volume":"9","author":"Isermann","year":"2003","journal-title":"Nat Med."},{"issue":"3","key":"2021100515301499400_B28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0020-7292(01)00534-3","article-title":"Ruptured corpus luteum cysts and anticoagulant therapy","volume":"76","author":"Jamal","year":"2002","journal-title":"Int J Gynaecol Obstet."},{"issue":"2","key":"2021100515301499400_B29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1210\/me.2011-1187","article-title":"Intraovarian thrombin and activated protein C signaling system regulates steroidogenesis during the periovulatory period","volume":"26","author":"Cheng","year":"2012","journal-title":"Mol Endocrinol."},{"issue":"12","key":"2021100515301499400_B30","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1182\/bloodadvances.2019001155","article-title":"A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation","volume":"4","author":"Okada","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"2021100515301499400_B31","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood-2014-02-557538","article-title":"A hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin (p.Cys537Stop)","volume":"124","author":"Langdown","year":"2014","journal-title":"Blood."},{"key":"2021100515301499400_B32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2020.11.002","article-title":"Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype","volume":"197","author":"Morrow","year":"2021","journal-title":"Thromb Res."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/19\/3830\/1824848\/advancesadv2020003814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/19\/3830\/1824848\/advancesadv2020003814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T16:17:28Z","timestamp":1633623448000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/19\/3830\/476764\/A-novel-homozygous-variant-of-the-thrombomodulin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":32,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2021,10,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003814","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]}}}